NGNE241115P30000
- 0.10
- 0.000.00%
Neurogene Newsroom
Neurogene Inc. Sees Significant Stock Purchases by Samsara BioCapital
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Neurogene and Ventyx Biosciences Rises After Insider Buying by Executives
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Neurogene CEO Rachel McMinn Acquires $968,999 in Stock
H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $55
Neurogene Price Target Maintained With a $55.00/Share by HC Wainwright & Co.
Positive Outlook on Neurogene's NGN-401 Despite Setback: Buy Rating Reaffirmed With $55 Price Target
Neurogene Adjusts Clinical Trial After Setback
Express News | Neurogene Shares Shares Down 5.5% After the Bell Following Announcement That Trial Participant Died, FDA Allowing It to Proceed With Trial for Rett Syndrome
Express News | Neurogene Inc - FDA Allows Neurogene to Proceed With Phase 1/2 Trial Using 1E15 Vg Dose
Express News | Neurogene Inc - Participant in Neurogene's Phase 1/2 Trial for Rett Syndrome Dies
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46
Express News | Neurogene Inc : Stifel Cuts Target Price to $46 From $60
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $46
TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating
Neurogene's Resilient Clinical Progress and Strong Financial Position Support Buy Rating
Neurogene Is Maintained at Outperform by BMO Capital
Neurogene Inc. Faces Uncertainty With NGN-101 Program Amid FDA Challenges and Strategic Hurdles
BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $60